The endocannabinoid system is spread throughout your brain and body, but primarily throughout your central nervous system. The interaction between cannabinoids and receptors is what produces effects like the regulation of mood, pain, appetite, inflammation, and memory. Plant-based cannabinoids, found in cannabis plants, also interact with the receptors (whimsically named CB1 and CB2) in the endocannabinoid system, and each affects your body in different ways. CBD and its infamous cousin THC are the 2 most well-known cannabinoids.
Moreover, a patient survey conducted by Project CBD, declared that “…cannabis appears to be an effective pain management tool with few negative side effects.” The study went on to say that a “…significant decrease in opiate usage among elderly patients while taking medical cannabis [was observed during trial].” In short, it has been portrayed clearly numerous times through valid and well-publicized clinical studies that cannabis is a practical option in terms of efficient pain management.
CBD is well tolerated in humans with doses up to 600 mg not resulting in psychotic symptoms (15). In the few small placebo-controlled studies performed, no significant CNS effects were noted. Oral CBD undergoes extensive first-pass metabolism via CYP3A4, with a bioavailability of 6%. Following single doses in humans, the half-life of CBD when taken orally is about 1 to 2 days.1 In vitro studies have shown that CBD is a potent inhibitor of multiple CYP isozymes, including CYP 2C and CYP3A (16, 17). Whether these in vitro observations are relevant at plasma concentrations likely to be seen in patients is unclear. In addition, given its metabolism via CYP3A4, clinical trials of CBD in patients receiving enzyme-inducing AEDs, such as carbamazepine or phenytoin, will require detailed pharmacokinetic studies.
Cunha et al. reported a 2-phase pilot study of CBD versus placebo in normal volunteers and patients with refractory secondarily generalized epilepsy (14). In the first phase, 8 normal volunteers received CBD or placebo in a doubled-blind fashion, at a dose of 3 mg/kg for 30 days. The second phase was also double-blinded in 15 patients with epilepsy receiving 200 to 300 mg daily of CBD or placebo for 135 days. Patients continued baseline AED. All subjects tolerated CBD well, with no serious adverse events. Four of the epilepsy patients receiving CBD were “almost free of convulsive crisis” for the duration of the study. Three other patients receiving CBD had a partial reduction in seizures, and 1 subject had no response. Of the 7 patients receiving placebo, seizure frequency was unchanged in 6, and 1 had clear improvement in seizure control.
Use a water bong and a healthstone if you already have them. Place a healthstone, which is a carbon-stone patty, into your bowl and scoop some CBD oil onto the end of a dabber. Then, hold the end of the dabber just over the healthstone and light the dabber with a lighter. This will heat up the dabber so that the oil falls onto the healthstone and becomes vaporized. Light the bowl and use the water bong normally, by inhaling through the mouthpiece.
Also listed among our low potency products is our bestselling CanChew® gum. With just 10 mg of CBD per piece of gum, it is easy to get started with CBD as a supplement, and adding more CBD to your diet is as simple as chewing another piece of gum. Another approachable product for those just starting out with CBD, CanChew® gum is a simple delivery method for getting your daily CBD.